Robust Clinical Data and Positive Customer Experience with T2Bacteria and T2Candida Panels Highlighted at Recent Medical Meetings
Presentations at ECCMID and MAD-ID meetings demonstrate clinically actionable results and cost savings achieved with these panels
Real-world experience reinforces multi-day time advantage demonstrated in the T2Bacteria 1,427-patient pivotal study, as compared to post-blood culture species identification tests
In April, case studies of patients tested with the
- Three T2Bacteria clinical cases were reviewed showing an approximately 24 hour to 37 hour time savings over direct-from-blood-culture MALDI Biotyper and one T2Bacteria clinical case of culture-negative sepsis missed altogether by blood culture but detected by the
T2Bacteria Panel . - Multiple T2Carba Resistance+ clinical cases were reviewed showing an average of a 30 hour time savings (ranging from approximately 2 to 90 hours) with T2Carba Resistance+ over direct-from-blood-culture PCR methods.
- For T2Bacteria panel, Dr. De Angelis concluded:
- “Study and clinical cases demonstrate the ability of theT2Bacteria Panel to detect infections and poly-microbial infections faster than blood culture.”
- “Clinical case study demonstrates the ability for T2Bacteria to detect probable infections missed by blood culture.”
- For the
T2Resistance Panel , Dr. De Angelis concluded:
- “Case studies demonstrate the opportunity for direct-from-blood resistance gene detection to provide results faster than blood culture-based diagnostics and to impact clinical care.”
In addition to Dr. De Angelis’ presentation during the Integrated Symposium, which was viewed by approximately 400 attendees, Professor
- Professor Bauer noted that “appropriate and rapid delivery of targeted antimicrobials is critical for surviving sepsis” and that rapid diagnostic tests can provide “cost savings with antimicrobial use as well as a reduction of length of stay associated costs.”
- Dr. Clancy provided patient case studies and noted that the
T2Bacteria Panel is appropriate for a variety of patients, including those in the high-risk intensive care unit and the emergency department. - Dr. Walsh concluded that the T2Bacteria and T2Candida Panels could improve outcomes for immunocompromised patients by providing earlier diagnosis and more sensitive detection of blood stream pathogens, thereby reducing length of stay and improving the chance of survival.
In addition, several poster presentations covering the T2Bacteria, T2Candida, and T2Resistance Panels were presented at ECCMID and the
In May, new data supporting the use of the T2Bacteria and T2Candida Panels to improve antimicrobial stewardship programs was presented at the 22nd Annual MAD-ID (Making a Difference in Infectious Diseases) Meeting, The Antimicrobial Stewardship Meeting in
- Dr.
Deanne Tabb of Piedmont Columbus Regional Midtown inColumbus, Georgia shared that use of theT2Bacteria Panel resulted in improved time to appropriate antibiotics and vancomycin trough goals, timely infectious diseases consultations for Staphylococcus aureus bacteremia and timely initiation of contact precautions. It also detected a case of blood culture negative K. pneumoniae pneumonia infection. - Dr.
Ryan Shields ofThe University of Pittsburgh Medical Center shared the successful results of T2Candida utilization as an antimicrobial stewardship tool, highlighting a 47% reduction in antifungal utilization.
All of the presentation slides and poster presentations from the ECCMID and MAD-ID meetings are available on the Publications and Presentations page of the T2 Biosystem’s website.
“The body of clinical evidence supporting the T2Bacteria and T2Candida Panels continues to grow, with impressive updates at the ECCMID and MAD-ID meetings,” said
The T2Bacteria and T2Candida Panels are the first and only
In addition, earlier this year, the Company announced that the
About T2 Biosystems
Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763
Investor Contact:
zkubow@w2ogroup.com
415-658-6436
Source: T2 Biosystems, Inc.